Held by 6 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $1.1B Position in Ascendis Pharma Avoro's substantial new position signals confidence in Ascendis's late-stage pipeline, particularly TransCon Growth Hormone (lonapegsomatropin) for growth hormone deficiency, which has generated positive Phase 3 data and faces an anticipated FDA decision in 2024.
AI analyst context — unlock full analysis
**Signal Note: OrbiMed Initiates $36.7M Position in Ascendis** OrbiMed's new $36.7M stake in Ascendis likely reflects conviction around lonapegsomatropin (TransCon Growth Hormone), a once-weekly growth hormone therapy with sustained PDUFA action expected in late 2024, targeting a $1.5B+ addressable market in pediatric GHD and adult GHD. The vote-of-confidence from a top-tier healthcare allocator signals confidence in regulatory approval timing and commercial potential, though execution risk remains on label breadth and payer adoption relative to daily GH analogs.
+ 4more — see how much conviction went in
See the Full Story